Articles producció científica> Medicina i Cirurgia

Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: Results from the EPIVAC cohort study

  • Identification data

    Identifier: imarina:6090048
    Handle: http://hdl.handle.net/20.500.11797/imarina6090048
  • Authors:

    Vila-Corcoles A
    Ochoa-Gondar O
    de Diego C
    Satue E
    Aragón M
    Vila-Rovira A
    Gomez-Bertomeu F
    Magarolas R
    Figuerola-Massana E
    Raga X
    Perez M
    Ballester F
  • Others:

    Author, as appears in the article.: Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez M; Ballester F
    Department: Medicina i Cirurgia
    URV's Author/s: Figuerola Massana, Enric / Gomez Bertomeu, Frederic-Francesc
    Keywords: Streptococcus pneumoniae Pneumonia Pneumococcal conjugate vaccine Effectiveness Adults pneumonia pneumococcal conjugate vaccine effectiveness adults
    Abstract: © 2018 The Author(s). Background: Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults. Methods: Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions. Results: Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7-88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0-678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8-2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75-1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97-1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48-1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either. Conclusion: Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.
    Thematic Areas: Zootecnia / recursos pesqueiros Saúde coletiva Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Infectious diseases Farmacia Ensino Engenharias iv Engenharias i Enfermagem Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Biotecnología Biodiversidade Astronomia / física
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 14712334
    Author's mail: enric.figuerola@urv.cat frederic-francesc.gomez@urv.cat
    Author identifier: 0000-0002-8039-2889
    Record's date: 2023-02-22
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3096-7
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Bmc Infectious Diseases. 18 (1): 196-
    APA: Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez M; Ba (2018). Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: Results from the EPIVAC cohort study. Bmc Infectious Diseases, 18(1), 196-. DOI: 10.1186/s12879-018-3096-7
    Article's DOI: 10.1186/s12879-018-3096-7
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    Publication Type: Journal Publications
  • Keywords:

    Infectious Diseases
    Streptococcus pneumoniae
    Pneumonia
    Pneumococcal conjugate vaccine
    Effectiveness
    Adults
    pneumonia
    pneumococcal conjugate vaccine
    effectiveness
    adults
    Zootecnia / recursos pesqueiros
    Saúde coletiva
    Odontología
    Nutrição
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Infectious diseases
    Farmacia
    Ensino
    Engenharias iv
    Engenharias i
    Enfermagem
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciências ambientais
    Biotecnología
    Biodiversidade
    Astronomia / física
  • Documents:

  • Cerca a google

    Search to google scholar